| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
Resolvin E1 (RvE1) is a lipid mediator derived from ω3 polyunsaturated fatty acids that exerts potent anti-inflammatory roles in several murine models. Anti-inflammatory mechanism of RvE1 in acquired immune responses has been attributed to attenuation of cytokine production by dendritic cells (DCs). In this study, we newly investigated the effect of RvE1 on DC motility using a contact hypersensitivity (CHS) model and found that RvE1 impaired DC motility in the skin using two-photon microscopy. RvE1 attenuated T cell priming in the draining lymph nodes and effector T cell activation in the skin, leading to the reduced skin inflammation in CHS. On the other hand, leukotriene B4 (LTB4) induced actin filament reorganization in DCs and increased DC motility by activating Cdc42 and Rac1 via BLT1, which was abrogated by RvE1. Our results suggest that RvE1 attenuates cutaneous acquired immune responses by inhibiting cutaneous DC motility possibly through LTB4-BLT1 signaling blockade.
|
